rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical and radiological remission of disease and to reduce functional limitations and permanent joint damage.

Rheumatoid%20arthritis Management

Follow Up

Monitoring for Drug Toxicity

  • Eg complete blood count, serum creatinine, liver function tests, hepatitis B and C screening, ophthalmologic exam, latent tuberculosis screening (for biological DMARDs, with chest X-ray)
  • Recommended prior to resuming or increasing therapy with DMARDs
  • It is important to monitor for toxicity due to the potential risks of serious adverse effects of DMARDs

Tapering of Therapy

  • For patients in persistent remission, can consider tapering biological or targeted synthetic DMARD therapy after tapering glucocorticoid therapy
    • Tapering of conventional synthetic DMARD therapy may also be considered
  • To decrease risk of flares, gradual withdrawal of biological therapies should be done
    • Flare risk is inversely proportional to disease activity and sustained response duration
  • As discontinuation of therapy is associated with high risk of flares, reduction of dose or increase in interval can be done with all biological and targeted synthetic DMARDs with little risk of flares 
    • Most patients who flare can regain their good state upon re-institution of the same biological or targeted synthetic DMARD therapy 
  • Ceasing treatment with conventional synthetic DMARDs is associated with increased flare frequency, hence tapering should be done cautiously and should be evaluated rigorously

Disease Activity Monitoring

  • Disease activity should be measured and documented regularly
    • Moderate-high disease activity: Monthly
    • Sustained low disease activity: Every 6 months
    • Clinical remission: Every 6 months (with DAS and DAS28)
    • Sustained remission: Every 3-6 months
  • Consider structural changes, comorbidities, and functional impairment when formulating treatment decisions on follow-ups
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.